Examining C3 Dominant Glomerulonephritis in the Egyptian Population
Prevalence and Pathological Features of C3 Dominant Glomerulonephritis Among Egyptian Population
This study looks at how common C3 dominant glomerulonephritis is in Egypt and what it looks like in kidney tissue to help understand this kidney disease better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06126471 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence and pathological features of C3 dominant glomerulonephritis among individuals in Egypt. It focuses on classifying cases based on the presence of predominant C3 fragment deposits in kidney tissues, which are indicative of abnormal complement activation. The study will analyze tissue samples with sufficient glomeruli and clinical data to better understand the disease's characteristics and implications. By identifying these features, the research seeks to enhance the understanding of C3 nephropathy and its variants in the Egyptian population.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with C3 dominant glomerulonephritis who have adequate kidney tissue samples for analysis.
Not a fit: Patients with other types of glomerular diseases, such as lupus nephritis or IgA nephropathy, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management strategies for patients with C3 nephropathy.
How similar studies have performed: While there may be limited studies specifically focused on C3 dominant glomerulonephritis in the Egyptian population, similar research on C3 glomerulopathy has shown promise in understanding the disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adequate sample with at least 10 glomeruli 2. Enough residual tissues in the paraffin blocks 3. Available clinical data Exclusion Criteria: Other glomerular diseases such as lupus nephritis, IgA nephropathy, membranous glomerulonephritis and immune complex-mediated membranoproliferative GN. Cases of minimal change were also excluded.
Where this trial is running
Sohag
- Sohag university , faculty of medicine — Sohag, Egypt (Recruiting)
Study contacts
- Principal investigator: Alaa Taha — Sohag university, faculty of medicine, Egypt
- Study coordinator: Alaa Taha
- Email: alaa_ali_taha154@yahoo.com
- Phone: 01000389590
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.